1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study holds significant promise for offering a powerful, non-surgical alternative to bariatric surgery for individuals with Type 2 Diabetes and Obesity, particularly within the veteran population. If successful, …
This study provides compelling evidence that liraglutide, a GLP-1 receptor agonist already approved for type 2 diabetes and weight management, can significantly improve liver fat and metabolic parameters in patients w…
The potential implications of a successful neuroprotective agent for Parkinson's Disease are immense, offering hope for slowing or halting disease progression. If liraglutide were shown to be effective, it could repre…
Optimizing treatment strategies for patients with Type 2 Diabetes and poor glycemic control is a critical unmet medical need, as uncontrolled blood sugar significantly increases the risk of severe complications. This …
This study is a methodological investigation designed to assess the concordance between real-world data analyses and the original SOUL Diabetes Trial results. As this record describes the study design and objectives r…
The current slow, sequential initiation of therapies for Type 2 Diabetes and CKD means patients often miss out on crucial early protection, leading to disease progression. This pilot study's findings could revolutioni…
Understanding these pharmacokinetic interactions is critical for the safe and effective use of the semaglutide and NNC0480-0389 combination, especially for patients who may also be taking oral contraceptives or pain r…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
Understanding the interplay between GLP-1 RA therapy and cardiac biomarkers like NT-proBNP and hs-cTnT is crucial for refining cardiovascular risk stratification in Type 2 Diabetes. This research could help identify p…
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This network meta-analysis provides a robust and comprehensive safety profile for oral Orforglipron, confirming its dose-dependent gastrointestinal side effects, which are common with GLP-1 RAs. The findings are cruci…
This research offers a novel and highly promising strategy for enhancing the oral delivery of peptide therapeutics, a long-standing challenge in pharmacology. By repurposing BBI, traditionally seen as an antinutrition…
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding sugg…
These preliminary findings are highly significant as they suggest semaglutide could be a viable pharmacologic option for adolescents battling MASLD, a condition currently lacking approved treatments. The observed impr…
This study provides compelling evidence that an intensive, short-term metabolic intervention can lead to sustained remission of Type 2 Diabetes, moving beyond mere disease management. The combination of IDegLira, metf…
The development of GZR18 represents a significant step towards addressing the unmet need for more convenient and effective long-term weight management solutions. The potential for a less frequent dosing regimen (every…
This systematic review provides compelling evidence that GLP1RAs offer a crucial therapeutic strategy for improving cardiovascular outcomes in a high-risk population previously less studied: obese individuals with ASC…
This study provides compelling economic evidence that semaglutide 2.4 mg is a highly cost-effective treatment option for obese patients with MASH in Italy. These findings are crucial for health policy makers and payer…
This real-world evidence strongly supports the significant benefits of GLP-1 RAs not only for metabolic control but also for dramatically improving the daily lives of patients with type 2 diabetes and obesity. The obs…
This post hoc analysis provides crucial insights, suggesting that semaglutide's cardiovascular protective effects are robust and extend beyond its weight-reducing capabilities. This finding reinforces the drug's value…
This research provides compelling evidence for a novel mechanism by which Tirzepatide protects against cisplatin-induced AKI, specifically through its ability to restore NAD+ levels and enhance mitochondrial quality c…
These findings are highly significant as they suggest tirzepatide offers superior kidney protection compared to dulaglagutide, a widely used GLP-1 agonist, in patients with Type 2 Diabetes. Given that chronic kidney d…
Understanding GLP-1's direct vascular effects could significantly expand its therapeutic potential beyond mere glucose control, offering new avenues for patient care. If GLP-1 or its analogues demonstrate independent …
This summary underscores that semaglutide offers more than just weight reduction; it significantly enhances the quality of life for people living with obesity. Recognizing these broader benefits is crucial for healthc…
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findin…
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could sig…
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in w…
This real-world data underscores the substantial weight-loss benefits of GLP-1 RAs, particularly tirzepatide, in patients with rheumatic and musculoskeletal diseases, a population often challenged by weight management…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This comprehensive "Evidence Map" highlights the transformative potential of incretin-based anti-obesity medications as a crucial therapeutic strategy for women suffering from PCOS and obesity. By consolidating existi…
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This study is significant because it sought to directly investigate the anti-inflammatory and chondroprotective (cartilage-protecting) potential of liraglutide, a GLP-1 receptor agonist, in knee osteoarthritis beyond …
The progressive decline of beta-cell function is a hallmark of Type 2 Diabetes Mellitus (T2DM), often leading to increased insulin dependence and uncontrolled blood sugar. If liraglutide were shown to preserve beta-ce…
The successful demonstration of bioequivalence means that this new Liraglutide injection can be considered therapeutically interchangeable with Victoza®. This is a significant step towards increasing patient access to…
This study is significant because it addresses a critical unmet need for effective and manageable weight loss interventions in a highly complex and often overlooked patient population. The successful completion of the…